Baillie Gifford & Co. lowered its position in Exscientia plc (NASDAQ:EXAI - Free Report) by 12.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 3,848,276 shares of the company's stock after selling 549,342 shares during the period. Baillie Gifford & Co. owned about 3.18% of Exscientia worth $18,780,000 at the end of the most recent quarter.
Other institutional investors have also bought and sold shares of the company. Olympiad Research LP bought a new position in shares of Exscientia in the third quarter worth about $448,000. China Universal Asset Management Co. Ltd. lifted its holdings in Exscientia by 66.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,576 shares of the company's stock worth $47,000 after purchasing an additional 3,821 shares in the last quarter. International Assets Investment Management LLC bought a new position in Exscientia in the 3rd quarter worth approximately $77,000. Novo Holdings A S purchased a new stake in Exscientia during the 2nd quarter valued at approximately $66,742,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Exscientia during the second quarter valued at approximately $256,000. Hedge funds and other institutional investors own 41.58% of the company's stock.
Exscientia Trading Down 3.6 %
Shares of NASDAQ EXAI traded down $0.21 during midday trading on Wednesday, reaching $5.61. 643,321 shares of the stock traded hands, compared to its average volume of 642,610. The company's 50 day moving average is $5.03 and its 200 day moving average is $5.14. Exscientia plc has a one year low of $3.80 and a one year high of $7.91. The company has a quick ratio of 5.93, a current ratio of 4.54 and a debt-to-equity ratio of 0.06.
Exscientia (NASDAQ:EXAI - Get Free Report) last released its quarterly earnings data on Thursday, August 15th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.05). Exscientia had a negative net margin of 882.09% and a negative return on equity of 49.10%. The business had revenue of $5.60 million for the quarter. On average, research analysts anticipate that Exscientia plc will post -1.25 EPS for the current year.
Wall Street Analyst Weigh In
Several research firms recently weighed in on EXAI. Barclays reaffirmed an "equal weight" rating and set a $5.00 target price on shares of Exscientia in a research note on Tuesday, August 13th. TD Cowen restated a "hold" rating on shares of Exscientia in a research report on Friday, August 9th.
Get Our Latest Research Report on EXAI
Exscientia Profile
(
Free Report)
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.
Read More
Before you consider Exscientia, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exscientia wasn't on the list.
While Exscientia currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
